Osteoprotegerin (OPG) and osteopontin (OPN) play a role in inhibiting the atherosclerotic plaque calcification in atherosclerosis in patients with PAD and T2D [138]. This evidence concerns the gene SPP1 and type 2 diabetes mellitus.